FDA WARNING_LETTER - TramadolHub

The FDA issued a Warning Letter to TramadolHub for offering unapproved and misbranded opioid products for sale to U.S. consumers, violating the Federal Food, Drug, and Cosmetic Act (FD&C Act). The letter highlights the public health concern given the opioid epidemic.

Specifically, TramadolHub's products, such as "OL-TRAM" (tramadol), are deemed "new drugs" under section 201(p) of the FD&C Act because they lack FDA approval for safety and effectiveness. Their introduction into interstate commerce without prior FDA approval violates sections 301(d) and 505(a) of the FD&C Act. Although FDA-approved tramadol exists, it carries a "black box warning" due to risks like addiction, respiratory depression, and neonatal opioid withdrawal syndrome, which are not addressed by TramadolHub's unapproved version.

Furthermore, the products are misbranded under section 502(f)(1) of the FD&C Act because they lack adequate directions for use by a layperson. As prescription drugs, they require supervision by a licensed practitioner and are not safe for self-diagnosis or treatment. Since they are unapproved, they are not exempt from this requirement under 21 CFR 201.115. This constitutes a violation of section 301(a) of the FD&C Act.

The FDA requires TramadolHub